Trividia Health Announces Jonathan Chapman as President and Chief Executive Officer
Trividia Health, Inc., a leading supplier of blood glucose monitoring systems, announced today that Jonathan Chapman has been appointed as President and Chief Executive Officer. Mr. Chapman succeeds Scott Verner in the role.
Mr. Chapman brings over 20 years of leadership experience in the medical device industry, with an accomplished track record of driving growth, developing strategic alliances, launching products globally, and optimizing business operations.
In addition to his newly assumed responsibilities at Trividia Health, Mr. Chapman will continue to serve as President and Chief Executive Officer of PTS Diagnostics, Inc.
“Jonathan has proven himself as the right leader for PTS Diagnostics and is the right leader for Trividia,” said Shaobo Li, Chairman of the Board at both Trividia Health and PTS Diagnostics. “Jonathan’s extensive background in successfully running medical device companies and his business development skills will help both organizations to reach the next level of growth and evolution. Jonathan is a results-oriented, dynamic, and innovative business leader. I am confident he has the right track record, commitment, vision and judgment to lead Trividia and PTS Diagnostics.”
“I’m honored to join the Trividia team as President and CEO. This organization has a long history of leadership within the healthcare industry as a provider of accurate, accessible, and affordable point-of-care solutions for the management of diabetes,” said Jonathan Chapman, President and CEO of Trividia Health and PTS Diagnostics. “I look forward to working with my colleagues at Trividia. With their support, focus on customers and continuing dedication, we will build on Trividia’s legacy of bringing leading innovation to patients across the globe.”
Mr. Chapman received a Bachelor of Arts from Sheffield University UK, LLM Commercial and Corporate Law from University of London (SOAS) and LLM Health Law from Hamline Law School, St. Paul, MN. Trividia is confident that his international experience will be immensely valuable when leading the organization across global markets.
About Trividia Health
Trividia Health, Inc., is a global health and wellness company with over 30 years experience in the industry. Based in Fort Lauderdale, Florida, Trividia is a leading developer, manufacturer and marketer of advanced performance products for people and pets with diabetes. With products sold under the TRUE brand, store brand labels and Healthy Tracks for Pets, the company is the exclusive partner and supplier of affordable, high-quality blood glucose monitoring and health and wellness solutions for the world’s leading retail pharmacies, distributors and mail service providers. For more information, please visit: www.TrividiaHealth.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210915005226/en/
Contact information
Neal Bhattacharya, Sr. Director, Product Marketing
(800) 342-7226, ext. 3150 – nbhattacharya@trividiahealth.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kaneka Expands Global Reach with i-ED COIL™ Launch in Europe10.11.2025 04:51:00 EET | Press release
Kaneka Corporation (Headquarters: Minato-ku, Tokyo; President: Kazuhiko Fujii) (TOKYO:4118) has begun sales of its i-ED COIL™, a brain aneurysm embolization coil (*1), in Europe as of October. The product obtained EC certification (*2) under an EU Medical Device Regulation (*3) in July and will be distributed primarily in Europe through Kaneka Medical Europe N.V. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251109744229/en/ i-ED Coil The i-ED COIL™ provides world-class flexibility, enabled by its specialized wire thickness and structural features. This flexibility enables coils to be packed more densely within aneurysms than conventional products and allows treatment of aneurysms with irregular shapes. Its role in reducing the risk of aneurysm rupture is highly regarded by physicians, and since its launch in the Japanese market in 2019, sales have continued to grow steadily. Kaneka is expanding its business in a wide range
Vertex Presents Updated Phase 1/2 Data From RUBY-3 Study That Continue to Demonstrate Best-in-Class Potential for Povetacicept in Adults with IgA Nephropathy and Primary Membranous Nephropathy at American Society of Nephrology Kidney Week9.11.2025 00:15:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced updated data for povetacicept (pove) in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) from the ongoing RUBY-3 trial at the American Society of Nephrology (ASN) Kidney Week 2025 in Houston, Texas. Pove is an investigational recombinant fusion protein therapeutic and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove is the only BAFF+APRIL inhibitor in pivotal trials for multiple kidney diseases. Results were presented today as a late-breaking oral presentation (SA-OR091) and included interim data from the open-label Phase 1/2 RUBY-3 trial, where adults with IgAN and pMN received pove subcutaneously every 4 weeks. The analysis included 21 participants with IgAN and 10 participants with pMN treated with pove at the 80mg dose, of which 17 participants and 5 participants, respectively, completed the Week 48 study visit. Results in IgAN In IgAN,
Westinghouse and Hungary Establish Landmark Nuclear Fuel Partnership8.11.2025 16:00:00 EET | Press release
Westinghouse Electric Company and MVM Group signed a contract to ensure diversification of fuel supply in Hungary. This partnership brings to Paks Nuclear Power Plant (NPP) reliable supply with Westinghouse VVER fuel, manufactured in Europe. The Westinghouse VVER-440 fuel reload deliveries will start in 2028, subject to licensing activities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251107682814/en/ Westinghouse Nuclear Fuel Senior Vice President Aziz Dag, left, and Károly Mátrai, CEO of the MVM Group, signed the Paks VVER-440 contract, Nov. 7, 2025. “Our agreement with Westinghouse is a clear response to today's energy challenges and further strengthens the role of Hungary's leading base power plant in the domestic energy supply. This strategically important step will make the operation of Paks Nuclear Power Plant safer and more flexible. The diversified fuel procurement reduces external exposures and provides predicta
OMRON Releases the “Medium-Term Roadmap SF 2nd Stage”8.11.2025 08:00:00 EET | Press release
OMRON (TOKYO: 6645) has announced its “Medium-Term Roadmap Shaping the Future 2nd Stage (“SF 2nd Stage”),” covering from FY2026 to FY2030, on November 7, 2025 (JST). This Roadmap presents the Group’s vision and growth strategies through 2030, which are disclosed on our corporate website. Overview of the “Medium-Term Roadmap SF 2nd Stage” Since April 2024, OMRON has been implementing a Structural Reform Program “NEXT 2025” aimed at rebuilding our foundation for profitability and growth. With the completion of this Program in September 2025, we have shifted into a growth phase and formulated a new Roadmap looking ahead to 2030. This Roadmap identifies Business Portfolio Restructuring as a core strategy. We have defined Thirteen Focus Businesses to drive the Group’s future growth. By accelerating our selection and concentration efforts, we aim to build a “distinctive” business portfolio that maximizes overall Group growth. Furthermore, to maximize the growth potential of our Focus Busines
26 th UN Tourism General Assembly kicks off in Riyadh7.11.2025 23:13:00 EET | Press release
The 26th session of the UN Tourism General Assembly opened today in Riyadh, marking a historic first for the Gulf Cooperation Council (GCC) region and the largest Assembly since UN Tourism was founded 50 years ago. Around 160 delegations from member states including ministers, senior officials, and leaders from across industry and civil society are coming together to celebrate five decades of international collaboration under the theme “AI-Powered Tourism: Redefining the Future.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251107012471/en/ 26th UN Tourism General Assembly kicks off in Riyadh The Assembly is hosted by Saudi Arabia’s Ministry of Tourism, with extensive cooperation and planning alongside UN Tourism and a wide range of partners. This collaboration underscores the Kingdom’s dedication to advancing the industry and facilitating impactful dialogue on the global stage. For half a century, UN Tourism has advanced
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom